Synergy of vaccination and agonist OX40 treatment-toward a mechanism-driven combination of glioma immunotherapy.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

1. A 1p/19q Codeletion-Associated Immune Signature for Predicting Lower Grade Glioma Prognosis.Cellular and molecular neurobiology · 2022
   Article
2. OX40 and OX40L protein expression of tumor infiltrating lymphocytes in non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers.Translational lung cancer research · 2019
   Article
3. Targeting Myeloid Cells in Combination Treatments for Glioma and Other Tumors.Frontiers in immunology · 2019
   Review

Corrections and comments

• Comment on
  Agonist OX40 immunotherapy improves survival in glioma-bearing mice and is complementary with vaccination with irradiated GM-CSF-expressing tumor cells.2018

Authors and funding

3 authors at 2 institutions in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as